The stock will trade on FREEDOM2 10 mg/kg data in 2H 2026 and resolution of the FDA partial clinical hold. Near-term catalyst is limited, monitor for FDA feedback and any preclinical study updates. The improved cash position reduces near-term dilution risk.
PEPG drugs
PEPG drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $1.78entry
- T+1 · 6mo ago 0.00%α +0.00% · $1.78
- T+5 · 6mo ago −22.47%α −21.31% · $1.38
- T+20 · 5mo ago −15.17%α −14.56% · $1.51
- T+60 · 3mo ago +60.11%α +55.67% · $2.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PepGen reported Q1 2026 net loss of $17.8M ($-0.26/share), narrower than the $30.2M loss in Q1 2025, with cash of $132.3M sufficient into 2H 2027. The FREEDOM2-DM1 5 mg/kg cohort showed favorable safety and efficacy data, the 10 mg/kg cohort is fully enrolled with data expected in 2H 2026, but an FDA partial clinical hold remains unresolved.
Key Financial Metrics
Key Facts
- Net loss of $17.8M ($-0.26/share) for Q1 2026 vs $30.2M ($-0.92/share) in Q1 2025
- Cash, cash equivalents and marketable securities of $132.3M as of March 31, 2026
- FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data
- FREEDOM2 10 mg/kg cohort fully enrolled, data on track for 2H 2026
- FDA partial clinical hold on FREEDOM2 study remains unresolved
- 13 patients enrolled in open label extension at 5 mg/kg with no discontinuations
Financial Impact
Net loss improved by $12.4M YoY to $17.8M; cash burn of $16.2M in Q1 2026
Risk Factors
- FDA partial clinical hold could delay or derail FREEDOM2 trial if not resolved
- 10 mg/kg cohort data may not replicate 5 mg/kg safety/efficacy profile
- Pre-revenue biotech with no approved products, binary clinical risk
- Cash runway only into 2H 2027, potential future dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-219424 |
| Document: pepg-20260512.htm | 0001193125-26-219424 |
| Document: 0001193125-26-219424-index-headers.html | 0001193125-26-219424 |
| Document: 0001193125-26-219424-index.html | 0001193125-26-219424 |
| Document: 0001193125-26-219424.txt | 0001193125-26-219424 |
| 8-K Data (Synthetic) | 0001193125-26-219424 |
Track record
12 reports on PEPG
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +31.95% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
- May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
- May 12, 202626w ago 8-K Neutral 5/10 Viewing Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers